Comment Comment by DrHilarius > The questions are all whether this one company had poor practices.If the FDA did not follow up on the whistleblower report it raises far broader questions about oversight of the trials as a whole. parent DrHilarius 4 years ago
If the FDA did not follow up on the whistleblower report it raises far broader questions about oversight of the trials as a whole.